Lymphoplasmacellular mucositis ameliorated by α4β7 integrin inhibitor vedolizumab in a patient with ulcerative colitis

Doaa Shalabi; Mansha Sethi; Lauren Okon; Gudrun F Debes; Jason B Lee; Neda Nikbakht

doi:10.1016/j.jdcr.2019.06.002

Lymphoplasmacellular mucositis ameliorated by α4β7 integrin inhibitor vedolizumab in a patient with ulcerative colitis

JAAD Case Rep. 2019 Jul 31;5(8):663-665. doi: 10.1016/j.jdcr.2019.06.002. eCollection 2019 Aug.

Authors

Doaa Shalabi¹, Mansha Sethi¹, Lauren Okon¹, Gudrun F Debes², Jason B Lee¹, Neda Nikbakht¹

Affiliations

¹ Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.
² Department of Microbiology and Immunology, Sidney Kimmel Medical College and Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

No abstract available

Keywords: ILPMD, idiopathic lymphoplasmacellular mucositis-dermatitis; UC, ulcerative colitis; idiopathic lymphoplasmacellular mucositis-dermatitis; inflammatory bowel disease; vedolizumab.

Publication types

Case Reports